OGN vs RAPP · P/E 3.4, rev $6.40B vs $532.9M cap
Organon & Co (OGN) versus Rapport Therapeutics, Inc. Common Stock (RAPP) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
RAPP does not have a complete income-statement cache yet.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. RAPP currently screens at market cap $532.9M.
Not investment advice. Open the OGN and RAPP stock pages for the full models.
Not investment advice.